Document is current

Article History

Received: 27 October 2020

Accepted: 21 April 2021

First Online: 3 May 2021

Declarations

:

: Not applicable. Attendance at the Sydney Workshop was by invitation and entirely voluntary, and workshop content did not require personal disclosures or involve any sensitivities. Workshop attendance alone does not require human research ethics committee approval under Australian regulations.

: Not applicable – no personal details are published in this paper.

: NL is supported by Yorkshire Cancer Research (Award S406NL) and reports personal fees from Pierre Fabre and Merck Sharp & Dohme outside the submitted work. DP reports non-financial support from Novo Nordisk, Eli Lilly, Sanofi-Aventis, Abbott, Medtronic and grants from Sanofi, outside the submitted work. AT reports personal fees from pharmaceutical companies outside the submitted work, and grants and consulting income to his employer from pharmaceutical companies, outside the submitted work. CH reports personal fees, honoraria and support from various companies with interests in the topic of the manuscript, outside the submitted work. AB is an employee of Amgen Australia. RLW is employed by the Commonwealth of Australia to chair the national health technology assessment committee (MSAC). LS and CD declare that they have no conflicts of interest.